• When oxybutynin is used in high environmental temperatures, this can cause heat prostration due to decreased sweating.The use of oxybutynin in children under 5 years of age is not recommended; it has not been established whether oxybutynin can be safely used in this age group.There is limited evidence supporting the use of Oxybutynin in children with monosymptomatic nocturnal enuresis (not related to detrusor overactivity).In children over 5 years of age, Oxybutynin hydrochloride should be used with caution as they may be more sensitive to the effects of the product, particularly the CNS and psychiatric adverse reactions. DITROPAN XL ® (oxybutynin chloride) is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.The symptoms of overdosage with oxybutynin progress from an intensification of the usual side effects of CNS disturbances (from restlessness and excitement to psychotic behaviour), circulatory changes (flushing, fall in blood pressure, circulatory failure etc), respiratory failure, paralysis and coma.Fever should be treated symptomatically with tepid sponging or ice packs.In pronounced restlessness or excitation, diazepam 10 mg may be given by intravenous injection, tachycardia may be treated by intravenous injection of propranolol and urinary retention can be managed by bladder catheterisation.In the event of progression of the curare- like effect to the paralysis of the respiratory muscles, mechanical ventilation will be required.Oxybutynin has both direct antispasmodic action on the smooth muscle of the bladder detrusor muscle as well as an anticholinergic action in blocking the muscarinic effects of acetylcholine on smooth muscle. • Narrow-angle glaucoma or shallow anterior chamber. (DITROPAN XL ® is also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).

These properties cause relaxation of the detrusor muscle of the bladder in patients with an unstable bladder.

Ditropan tablets 2.5mg are pale blue oval bi-convex tablets 8 mm x 5.5 mm, ... Paediatric population. Available for Android and iOS devices.

Patients should be cautioned regarding activities requiring mental alertness such as driving, operating machinery or performing hazardous work while taking this drug.Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).

Paediatric population. Oxybutynin, as an anticholinergic agent, may antagonize the effect of prokinetic therapies.Concomitant use with cholinesterase inhibitors may result in reduced cholinesterase inhibitor efficacy.Patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic agents such as oxybutynin (see section 4.7).Oxybutynin may cause drowsiness or blurred vision. • Gastrointestinal obstructive disorders including paralytic ileus, intestinal atony. INDICATIONS.

• Urinary incontinence, urgency and frequency in unstable bladder conditions due to idiopathic overactive bladder or neurogenic bladder disorders (detrusor overactivity). eMedTV serves only as an informational resource. It is highly bound to plasma proteins, the peak plasma level is reached between 0.5 to 1 hour after administration.

When suggestions are available use up and down arrows to review and ENTER to select. Oxybutynin hydrochloride is indicated in children over 5 years of age for: • Urinary incontinence, urgency and frequency in unstable bladder conditions due to idiopathic overactive bladder or neurogenic bladder disorders (detrusor overactivity).